Hemostatic changes in patients with brain tumors.
Abnormal hemostasis is a functional property of cancer. Hemostatic abnormalities are common in patients with systemic malignant disease and brain tumors. However, the incidence of thromboembolism is higher in patients with brain tumors than in those with systemic disease. This raises the question of whether or not hemostatic abnormalities found in the blood of the two groups of patients differs, suggesting different pathogeneses. The purpose of this report is to review abnormalities in blood and clinical manifestations of abnormal hemostasis found in brain tumors and cancer patients in an attempt to answer this question. Normal hemostasis, as currently understood, will be considered with an emphasis on features unique to the central nervous system.
Thoron
L
L
Department of Surgery, Memorial Sloan-Kettering Cancer Center, New York, New York 10021, USA.
Arbit
E
E
D001777:Blood Coagulation; D001932:Brain Neoplasms / Q000097:blood* / Q000150:complications; D004211:Disseminated Intravascular Coagulation / Q000209:etiology; D005342:Fibrinolysis; D006487:Hemostasis; D006801:Humans; D009369:Neoplasms / Q000097:blood / Q000150:complications